Ayala Pharmaceuticals Inc (ADXS) USD0.001

Sell:$0.70Buy:$0.70Price increased$0.06 (9.98%)

Prices delayed by at least 15 minutes
Sell:$0.70
Buy:$0.70
Change:Price increased$0.06 (9.98%)
Deal now
Prices delayed by at least 15 minutes
Sell:$0.70
Buy:$0.70
Change:Price increased$0.06 (9.98%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine.

Key people

Kenneth A. Berlin
President, Chief Executive Officer, Director
David Sidransky
Independent Chairman of the Board
Vered Bisker- Leib
Independent Vice Chairman of the Board
Yuval Cabilly
Director
Bridget A. Martell
Director
Pini Orbach
Director
Click to see more

Key facts

  • Shares in issue
    42.67m
  • EPIC
    ADXS
  • ISIN
    US0076244062
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $20.55m
  • Employees
    20
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.